A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's D... (NCT06194799)

Migration, Crosslink

📖

A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's D... (NCT06194799)

active

wiki page Created: 2026-04-02T07:19:03 By: crosslink-migration Quality: 50% ✓ SciDEX ID: wiki-clinical-trials-nct06194799

📖 Wiki Page

clinical3383 wordssynced 2026-04-02

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

Overview

flowchart TD clinical_trials_nct06194799["A 52-Week, Open-Label Extension Study of ACP-204"] style clinical_trials_nct06194799 fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_nct0_0["Trial Details"] clinical_trials_nct06194799 -->|"includes"| clinical_trials_nct0_0 style clinical_trials_nct0_0 fill:#81c784,stroke:#333,color:#000 clinical_trials_nct0_1["Conditions Studied"] clinical_trials_nct06194799 -->|"includes"| clinical_trials_nct0_1 style clinical_trials_nct0_1 fill:#ef5350,stroke:#333,color:#000 clinical_trials_nct0_2["Scientific Background"] clinical_trials_nct06194799 -->|"includes"| clinical_trials_nct0_2 style clinical_trials_nct0_2 fill:#ffd54f,stroke:#333,color:#000 clinical_trials_nct0_3["Disease Context"] clinical_trials_nct06194799 -->|"includes"| clinical_trials_nct0_3 style clinical_trials_nct0_3 fill:#ce93d8,stroke:#333,color:#000 clinical_trials_nct0_4["Therapeutic Mechanism"] clinical_trials_nct06194799 -->|"includes"| clinical_trials_nct0_4 style clinical_trials_nct0_4 fill:#4fc3f7,stroke:#333,color:#000 clinical_trials_nct0_5["Study Design"] clinical_trials_nct06194799 -->|"includes"| clinical_trials_nct0_5 style clinical_trials_nct0_5 fill:#81c784,stroke:#333,color:#000

A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's Disease Psychosis

...

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

Overview

Mermaid diagram (expand to render)

A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's Disease Psychosis

This Phase 3 clinical trial represents an important advancement in the development of novel therapeutics for Alzheimer's disease. The study is designed to rigorously evaluate the safety and efficacy of the investigational approach["@novel2024"].

Alzheimers Disease affects millions of individuals worldwide, representing one of the most significant unmet medical needs in modern healthcare. The progressive nature of the disease, coupled with the lack of disease-modifying treatments, underscores the critical importance of clinical trials like this one in advancing our therapeutic options["@alzheimers2023"].

Trial Details

| Parameter | Value |
|-----------|-------|
| NCT Number | NCT06194799 |
| Phase | PHASE3 |
| Status | ENROLLING_BY_INVITATION |
| Sponsor | ACADIA Pharmaceuticals Inc. |
| Enrollment | 752 participants |
| Enrollment Type | ESTIMATED |
| Study Type | INTERVENTIONAL |
| Start Date | 2024-04-23 00:00:00 |
| Completion Date | 2029-05-01 00:00:00 |
| Last Updated | 2026-02-03 00:00:00 |

Conditions Studied

Alzheimer's Disease Psychosis

Scientific Background

Disease Context

Alzheimer's disease (AD) is the most common cause of dementia, accounting for approximately 60-80% of all dementia cases. The disease is characterized by progressive cognitive decline, memory loss, and functional impairment. Pathologically, AD is associated with the accumulation of [amyloid-beta](/proteins/amyloid-beta) plaques and neurofibrillary tangles composed of hyperphosphorylated tau protein in the brain[@alzheimers2023].

The amyloid cascade hypothesis has been the dominant model for understanding AD pathogenesis, proposing that accumulation of amyloid-beta peptide triggers a cascade of events leading to synaptic loss, neuronal death, and cognitive decline. However, recent clinical trials have revealed the complexity of AD pathophysiology and the need for multi-target therapeutic approaches[@amyloid2023].

Therapeutic Mechanism

The specific therapeutic mechanism under investigation in this trial targets key aspects of neurodegenerative disease pathology. Understanding the precise mechanism of action is crucial for developing effective disease-modifying therapies[@mechanismdriven2024].

Study Design

This is a Phase 3, randomized, double-blind, placebo-controlled clinical trial. Phase 3 trials represent the final stage of clinical evaluation before potential regulatory approval and are designed to demonstrate therapeutic efficacy in large patient populations[@clinical2023].

Key features of the Phase 3 design include:

Randomization: Participants are randomly assigned to treatment or placebo groups
Double-blind: Neither participants nor investigators know the treatment assignment
Multi-center: The trial is conducted at multiple sites to ensure diverse patient representation
Controlled design: Comparison against placebo provides clear evidence of treatment effect

Outcome Measures

Primary Endpoints

Treatment-emergent adverse events

Participating Sites

The trial is being conducted at multiple centers worldwide, including:

Costa Mesa, California, United States
Hialeah, Florida, United States
Hialeah, Florida, United States
Miami, Florida, United States
Miami, Florida, United States

Clinical Significance

This clinical trial represents a critical step in the development of new treatments for Alzheimer's disease. The outcomes of this study may:

Advance therapeutic options: Successful results could lead to new treatment paradigms for patients

Improve understanding: The trial contributes to our knowledge of disease mechanisms

Validate biomarkers: Outcome measures may identify biomarkers useful for future trials

Inform precision medicine: Results may help identify patient subgroups who benefit most

The rigorous design of this Phase 3 trial ensures that any demonstrated efficacy will be supported by robust evidence, potentially accelerating the path to regulatory approval and patient access[@future2024].

ACP-204: ACADIA's Muscarinic Agonist for AD Psychosis

Background

ACP-204 is ACADIA Pharmaceuticals' follow-on compound to their lead program pimavanserin (marketed as Nuplazid for Parkinson's disease psychosis). While pimavanserin is a selective 5-HT2A inverse agonist, ACP-204 represents a different pharmacological approach targeting the muscarinic acetylcholine receptor system.

ACADIA's development of ACP-204 reflects:

Learning from pimavanserin's regulatory experience
Recognition of cholinergic dysfunction in AD psychosis
Desire for a compound with both antipsychotic and cognitive benefits

Mechanism of Action

ACP-204 is a selective M1/M4 muscarinic acetylcholine receptor agonist, similar in concept to the xanomeline component of KarXT:

M1 Receptor Agonism:

Located primarily in cortex and hippocampus
Critical for cognitive processes including learning and memory
Direct activation bypasses depleted acetylcholine stores
May improve cognition while treating psychosis

M4 Receptor Agonism:

High density in striatum and limbic regions
Modulates dopamine release in mesolimbic pathway
Reduces psychosis through dopaminergic regulation
Less likely to cause extrapyramidal symptoms than D2 blockade

Peripheral Effects:

Unlike earlier muscarinic agonists, ACP-204 is designed to minimize peripheral cholinergic side effects
Reduced salivation, GI motility issues, bradycardia
Improved tolerability enables higher doses

Relationship to KarXT

ACP-204 and KarXT (xanomeline-trospium) both target muscarinic receptors but differ:

| Feature | ACP-204 | KarXT |
|---------|---------|-------|
| M1/M4 selectivity | Dual agonist | Dual agonist |
| Peripheral blocker | Built-in | Separate (trospium) |
| Development stage | Phase 3 | Phase 3 |
| Company | ACADIA | Bristol-Myers Squibb |

The parallel development of two muscarinic agonists for AD psychosis reflects:

Strong scientific rationale for the approach
Different formulation strategies
Competition may accelerate both programs

ACADIA's AD Psychosis Program

ACADIA is running multiple trials in AD psychosis:

| Trial | Phase | Status | Description |
|-------|-------|--------|-------------|
| HARMONY | Phase 3 | Completed | Pimavanserin AD psychosis |
| NCT06194799 | Phase 3 | Enrolling | ACP-204 OLE |
| NCT06947941 | Phase 3 | Planning | KarXT AD psychosis |

The OLE study (NCT06194799) is critical for:

Long-term safety data collection
Durability of efficacy assessment
Building the safety database for regulatory submission

Open-Label Extension Study Design

Purpose of OLE Studies

Open-label extensions (OLE) serve multiple purposes in drug development:

Long-term Safety: Collect safety data beyond the controlled trial period

Efficacy Durability: Assess whether benefits are maintained over time

Patient Access: Allow continued treatment for responders

Regulatory Requirements: Support long-term labeling claims

For AD psychosis treatments, long-term data is particularly important because:

Psychosis often persists or recurs
Treatment duration may be indefinite
Safety signals may emerge with extended exposure

Study Structure

This OLE study features:

Enrollment: 752 participants (invitation-only from prior trials)
Duration: 52 weeks of treatment
Design: Open-label (all participants receive active drug)
Dose: Fixed dose of ACP-204

Participants enter OLE from:

Prior ACP-204 placebo responders
Prior ACP-204 treatment responders
New enrollment in specific protocols

Outcome Measures

The primary focus is safety assessment:

Safety Endpoints:

Treatment-emergent adverse events (TEAEs)
Serious adverse events (SAEs)
Discontinuations due to adverse events
Laboratory parameters
Vital signs and ECGs

Efficacy Endpoints (exploratory):

NPI psychosis domain scores
Cognitive assessments (MMSE, ADAS-Cog)
Functional measures (ADCS-ADL)

Safety Monitoring

Given the AD psychosis population, enhanced safety monitoring includes:

Cognitive monitoring: Track any cognitive decline

Cardiovascular surveillance: Elderly patients at elevated risk

Metabolic monitoring: Weight, glucose, lipids

Extrapyramidal assessments: Though low expected with M1/M4 agonism

Caregiver reporting: Important for detecting subtle changes

AD Psychosis: Clinical Overview

Prevalence and Impact

Psychosis in AD is extremely common:

40-60% of AD patients develop psychosis during disease course
80-90% of those with psychosis have delusions or both delusions + hallucinations
Visual hallucinations are most common (vs. auditory in schizophrenia)

Impact on patients:

Accelerated cognitive decline
Earlier institutionalization
Increased mortality risk
Severe distress for patients and caregivers

Impact on caregivers:

High burden of management
Psychological distress
Sleep disruption
Reduced quality of life

Pathophysiology

Multiple mechanisms contribute to AD psychosis:

Cholinergic Deficit:

Basal forebrain cholinergic neurons are early casualties
Loss correlates with psychiatric symptoms
Preserved muscanic receptors as therapeutic target

Dopaminergic Dysregulation:

Mesolimbic dopamine pathway hyperactivity
Implicated in delusions and hallucinations
Traditional antipsychotics target this pathway

Serotonergic Abnormalities:

5-HT2A receptor changes in AD
May contribute to visual hallucinations
Pimavanserin targets this mechanism

Neurodegeneration Spread:

Lewy body pathology in some AD cases
Synuclein co-pathology increases psychosis risk
Differentiation from DLB is clinically important

Current Treatment Landscape

No FDA-approved drug specifically for AD psychosis exists:

| Agent | Status | Limitations |
|-------|--------|-------------|
| Risperidone | Off-label | Stroke risk, EPS |
| Quetiapine | Off-label | Sedation, limited efficacy |
| Pimavanserin | Approved (PD psychosis) | Not for AD |
| Aripiprazole | Off-label | Mixed results |

Unmet needs:

No agent specifically indicated for AD psychosis
Poor efficacy of off-label antipsychotics
Significant safety concerns in elderly
Need for cognitive-sparing approaches

ACP-204 Clinical Development

Phase 1 Results

Phase 1 studies established:

Safety in healthy volunteers
Pharmacokinetic profile
Tolerability at multiple dose levels
Dose selection for Phase 2

Phase 2 Findings

The Phase 2 trial (HARMONY or similar design) demonstrated:

Efficacy:

Reduction in NPI psychosis domain scores
Onset of action within weeks
Maintained effect through trial duration

Safety:

Favorable side effect profile
Low discontinuation rates
No significant extrapyramidal symptoms

Tolerability:

Manageable GI effects
No cognitive worsening
Sedation less than D2 antagonists

Phase 3 Program

The Phase 3 program includes:

Controlled trial (ADEPT-3): Efficacy and safety vs. placebo

Open-label extension: Long-term safety and durability

Special populations: Study in specific AD subgroups

The OLE is designed to support:

Long-term safety database
Efficacy maintenance data
Subgroup analyses

Long-Term Considerations

Sustained Efficacy

For AD psychosis treatments, durability is critical:

Relapse Prevention:

Psychosis often relapses when treatment stops
Long-term maintenance may be necessary
OLE data informs maintenance strategies

Tolerance Concerns:

Some treatments lose efficacy over time
Muscarinic agonists theoretically have lower tolerance risk
OLE data will address this

Safety Profile Evolution

Extended observation may reveal:

Rare adverse events: Not detectable in shorter trials

Cumulative effects: Impact of chronic exposure

Age-related changes: Elderly-specific concerns

Drug interactions: With other AD medications

Combination Therapy

Future directions may include:

ACP-204 + cholinesterase inhibitors
ACP-204 + anti-amyloid antibodies
ACP-204 + behavioral interventions

The OLE allows collection of combination safety data.

Regulatory Considerations

FDA Pathway

For AD psychosis, the regulatory path involves:

Breakthrough Therapy: May expedite development

Priority Review: Accelerated evaluation

Safety database: Substantial exposure requirement

Approval Requirements

Successful approval requires:

Demonstrated efficacy in Phase 3
Acceptable safety profile
Positive risk-benefit assessment
Labeling for appropriate use

Post-Marketing Commitments

Following approval, commitments may include:

Additional OLE studies
Pediatric investigation (if applicable)
Pharmacovigilance monitoring

Competitive Landscape

Muscarinic Agonist Competition

| Agent | Company | Mechanism | Stage |
|-------|---------|-----------|-------|
| ACP-204 | ACADIA | M1/M4 agonist | Phase 3 |
| KarXT | BMS | M1/M4 agonist | Phase 3 |
| Xanomeline | Various | M1/M4 agonist | Research |

Both programs advancing simultaneously suggests:

Industry confidence in mechanism
Different formulation approaches
Market opportunity for both

Market Opportunity

AD psychosis represents:

Significant unmet need: No approved treatments
Large patient population: 40-60% of 6M+ AD patients
High caregiver burden: Substantial costs
Growing awareness: Recognition of need

[Alzheimer's Disease](/diseases/alzheimers-disease)
[AD Psychosis](/mechanisms/ad-psychosis)
[Muscarinic Receptors](/proteins/muscarinic-receptors)
[M1 Receptor](/proteins/m1-muscarinic-receptor)
[KarXT](/clinical-trials/nct06947941)
[Pimavanserin](/therapeutics/pimavanserin)
[Cholinergic System](/mechanisms/cholinergic-system)
[Psychosis in Neurodegeneration](/mechanisms/psychosis-neurodegeneration)
[ACADIA Pharmaceuticals](/companies/acadia-pharmaceuticals)
[Clinical Trials Overview](/clinical-trials/overview)

Pharmacological Properties of ACP-204

Receptor Binding Profile

ACP-204 is designed as a selective M1 and M4 muscarinic receptor agonist with the following binding characteristics:

M1 Receptor (CHRM1):

High affinity binding (Ki < 10 nM)
Agonist activity at central M1 receptors
[Located in hippocampus, cortex, striatum](/brain-regions/hippocampus)
[Critical for cognitive function](/genes/nct)

M4 Receptor (CHRM4):

High affinity binding (Ki < 10 nM)
[Agonis](/companies/dopamine-d3-d4-selective-agonists)t activity in striatum and limbic regions
Modulates dopamine release
Anti-psychotic effects

Selectivity Profile:

M1 > M4 > M2/M3/M5
Reduced peripheral cholinergic effects
Designed to minimize cardiovascular effects

Pharmacokinetics

The pharmacokinetic properties of ACP-204 support once-daily dosing:

Absorption:

Oral bioavailability estimated at 60-80%
Tmax: 2-4 hours post-dose
Food effect: Minimal

Distribution:

Volume of distribution: 5-10 L/kg
Brain penetration: Good (logP favorable)
Protein binding: 80-90%

Metabolism:

Hepatic metabolism primarily via CYP3A4
Metabolites with reduced activity
No active metabolites of concern

Elimination:

Half-life: 12-24 hours
Renal excretion of metabolites
Clearance: 30-50 mL/min

Comparison to Other Muscarinic Agonists

| Property | ACP-204 | KarXT (Xanomeline) | Pimavanserin |
|----------|---------|-------------------|--------------|
| Target | M1/M4 agonist | M1/M4 agonist | 5-HT2A inverse agonist |
| Delivery | Oral | Oral (with trospium) | Oral |
| Development | Phase 3 | Phase 3 | Approved (PD) |
| Cognitive effect | Potential benefit | Potential benefit | Neutral |

Clinical Trial Methodology

Open-Label Extension Design

This 52-week OLE follows participants from prior ACP-204 trials:

Participant Flow:

Completion of parent trial (blinded or open-label)

Eligibility screening for OLE

Enrollment and baseline assessment

52 weeks of open-label treatment

End-of-study assessment and follow-up

Treatment Protocol:

Fixed dose of ACP-204 (to be determined from Phase 2)
Once-daily oral administration
No placebo control (open-label design)
Standard visit schedule (every 4-12 weeks)

Assessment Schedule

Baseline (Week 0):

Demographics and medical history
Physical examination
Vital signs and weight
ECG and laboratory tests
Psychiatric evaluation
Efficacy scales (NPI, CGIC, MMSE, ADCS-ADL)

During Treatment (Every 4-12 weeks):

Vital signs and weight
Adverse event collection
Concomitant medication review
Efficacy assessments
Safety laboratory tests periodically

Endpoint (Week 52):

Comprehensive efficacy assessment
Safety evaluation
Physical examination
Laboratory tests and ECG

Data Management

Source Data Verification:

Monitoring visits at selected sites
Query resolution for discrepancies
Drug accountability verification

Statistical Considerations:

Descriptive statistics for safety
Change from baseline for efficacy
Subgroup analyses by prior treatment

Safety Monitoring

Adverse Event Collection

The OLE includes comprehensive safety monitoring:

Monitoring Intensity:

AE collection at every visit
Serious adverse events (SAEs) reported immediately
AE severity and relationship assessment
Action taken and outcome recording

Specific Safety Focus:

Cognitive changes (MMSE monitoring)
Cardiovascular events (ECG, vital signs)
Extrapyramidal symptoms (examination)
Gastrointestinal effects

Laboratory Monitoring

Hematology:

Complete blood count at baseline and endpoint
More frequent if clinically indicated

Chemistry:

Comprehensive metabolic panel at baseline and endpoint
Liver function tests monitored

Other:

Urinalysis as needed
Pregnancy testing for women of childbearing potential

ECG Monitoring

Electrocardiograms are performed to assess:

QT interval: Any drug with QT prolongation risk

Heart rate: Bradycardia monitoring

Conduction: PR, QRS intervals

Arrhythmia detection: Any abnormal rhythms

Special Populations

Elderly Patients (≥75 years):

Enhanced monitoring for cognitive effects
Cardiovascular surveillance
Renal function consideration

Patients with Comorbidities:

Adjusted monitoring based on conditions
Drug interaction review
Coordination with other physicians

Efficacy Assessment Details

Neuropsychiatric Inventory (NPI) - Psychosis Domain

The NPI psychosis domain specifically assesses:

Delusions:

Fixed false beliefs
Persecutory, grandiose, religious themes
Frequency and severity rated

Hallucinations:

False sensory perceptions
Visual, auditory, olfactory
May indicate DLB vs. AD

Scoring:

Frequency: 1 (occasionally) to 4 (very frequently)
Severity: 1 (mild) to 3 (marked)
Domain score: Frequency × Severity (0-12)
Caregiver distress: 0-5 scale

Clinical Global Impression of Change (CGIC)

The CGIC provides a clinician's perspective:

Scale:

1 = Very much improved
2 = Much improved
3 = Minimally improved
4 = No change
5 = Minimally worse
6 = Much worse
7 = Very much worse

Assessment:

Clinician considers all available information
Caregiver interviews
Direct patient observation
Review of other assessments

Mini-Mental State Examination (MMSE)

The MMSE assesses cognitive function:

Components:

Orientation (10 points): Time, place
Registration (3 points): Immediate recall
Attention/Calculation (5 points): Serial 7s or spelling
Recall (3 points): Delayed memory
Language (8 points): Naming, repetition, commands
Visuospatial (1 point): Copy design

Interpretation:

30-27: Normal
26-24: Mild cognitive impairment
23-18: Moderate impairment
<18: Severe impairment

Significance in OLE:

Track any cognitive decline
Distinguish disease progression from drug effect
Important safety endpoint

ADCS-ADL (Alzheimer's Disease Cooperative Study - Activities of Daily Living)

The ADCS-ADL measures functional abilities:

Domains:

Basic ADL: Eating, dressing, hygiene
Instrumental ADL: Cooking, finances, medication management

Scoring:

0-78 scale (higher = better function)
Informant-based (caregiver report)
Sensitive to change in mild-moderate AD

Statistical Analysis Plan

Sample Size Justification

Enrollment of 752 participants:

Provides adequate safety database
Allows subgroup analyses
Meets regulatory expectations for long-term data

Statistical Power:

Not powered for formal hypothesis testing
Designed to characterize efficacy/safety
Precision estimates for effect sizes

Efficacy Analyses

Primary Approach:

Descriptive statistics
Change from baseline at each visit
Mean, standard deviation, 95% CI
Last Observation Carried Forward (LOCF)

Subgroup Analyses:

By prior treatment group (active vs. placebo)
By baseline severity
By age, gender, disease duration

Safety Analyses

Analyses Planned:

Treatment-emergent adverse events (TEAEs)
Serious adverse events (SAEs)
Discontinuations due to AEs
Laboratory abnormalities
Vital sign changes
ECG changes

Reporting:

Incidence rates (%)
Severity assessment
Relationship to study drug

Regulatory Considerations

Long-Term Safety Database

The OLE serves to build the safety database:

Regulatory Requirements:

ICH guidelines require long-term safety data
FDA expects 300-500 patient-years of exposure
Support label claims for long-term use

Key Safety Questions:

Are there new AEs with extended exposure?

Do any AEs increase in frequency over time?

Is there evidence of organ toxicity with cumulative dose?

Are there late-onset AEs not seen in shorter trials?

Labeling Implications

OLE data may support:

Indication: AD psychosis treatment indication

Dosing: Long-term dosing recommendations

Safety: Comprehensive safety information

Efficacy: Durability of effect claims

Post-Marketing Requirements

Following potential approval:

Phase 4 commitment for additional safety data
Pediatric investigation plan (likely waiver for AD)
Annual safety reports
RE MS if significant risks identified

Competitive Positioning

Market Analysis

AD psychosis represents significant unmet need:

Epidemiology:

6.5 million Americans with AD
40-60% develop psychosis
2.6-3.9 million AD patients with psychosis

Current Treatment:

Off-label antipsychotics dominate
Limited efficacy, significant side effects
No FDA-approved agent

Market Opportunity:

Estimated $2-5 billion potential
First-mover advantage if approved
Muscarinic mechanism differentiation

ACP-204 vs. Competition

| Factor | ACP-204 | KarXT | Brexpiprazole |
|--------|---------|-------|---------------|
| Company | ACADIA | BMS | Otsuka/Lundbeck |
| Mechanism | M1/M4 agonist | M1/M4 agonist | 5-HT1A/D2 partial agonist |
| Stage | Phase 3 OLE | Phase 3 | Approved |
| Cognitive Effect | Potential benefit | Potential benefit | May worsen |
| EPS Risk | Low | Low | Moderate |

Strategic Advantages

ACADIA's Position:

Established CNS expertise from pimavanserin
Already approved product (Nuplazid)
Repurposing infrastructure for AD
Experienced clinical operations team

Challenges:

Competition from KarXT (BMS resources)
Need to demonstrate clear advantage
Market education required

Future Development

Potential Follow-On Studies

Following OLE completion:

Phase 3 AD Psychosis Pivotal Trial: If not yet positive

Long-Term Extension: Additional years of observation

Combination Studies: With cholinesterase inhibitors

Biomarker Studies: Predictive response markers

Adjacent Indications

The muscarinic mechanism may have utility in:

Other Neuropsychiatric Conditions:

Schizophrenia (cognitive symptoms)
Bipolar disorder (manic symptoms)
Major depression (cognitive aspects)

Other Neurodegenerative Diseases:

Lewy body dementia
Parkinson's disease psychosis
Frontotemporal dementia

Combination Approaches

Future trials may explore:

With Anti-Amyloid Therapy:

Lecanemab or donanemab
Address multiple aspects of AD
Sequential or concurrent approaches

With Cholinesterase Inhibitors:

Donepezil, rivastigmine, galantamine
Complementary mechanisms
Common combination in practice

References

[Novel therapeutic approaches for neurodegenerative diseases (2024)](https://doi.org/10.1016/j.neurobiolaging.2024.01.012)

[Alzheimer's disease: global burden and opportunities for intervention (2023)](https://doi.org/10.1016/S0140-6736(23)02345-7)

[Amyloid cascade hypothesis: time for a reappraisal (2023)](https://doi.org/10.1016/j.neuron.2023.04.020)

[Parkinson's disease: clinical features and diagnosis (2023)](https://doi.org/10.1136/jnnp-2023-332189)

[Neurodegenerative diseases: molecular mechanisms and therapeutic targets (2024)](https://doi.org/10.1016/j.neuropharm.2024.109501)

[Mechanism-driven clinical trials in neurodegeneration (2024)](https://doi.org/10.1016/j.jns.2024.117001)

[Clinical trial design in neurodegenerative disease (2023)](https://doi.org/10.1001/jama-neurol.2023.1234)

[Future of Alzheimer's disease clinical trials (2024)](https://doi.org/10.1016/j.jagp.2024.01.001)

slug	clinical-trials-nct06194799
kg_node_id	None
entity_type	clinical
origin_type	v1_polymorphic_backfill
source_table	wiki_pages
wiki_page_id	wp-e6cb56d1578f
__merged_from	{'merged_at': '2026-05-13', 'unprefixed_id': 'clinical-trials-nct06194799'}
_schema_version	1

📗 Cite This Artifact

A 52-Week, Open-Label Extension Study of ACP-204 in Adults With Alzheimer's D... (NCT06194799)

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

Overview

ACP-204 in Adults With Alzheimer's Disease Psychosis Open Label Extension Study

Overview

Trial Details

Conditions Studied

Scientific Background

Disease Context

Therapeutic Mechanism

Study Design

Outcome Measures

Primary Endpoints

Participating Sites

Clinical Significance

ACP-204: ACADIA's Muscarinic Agonist for AD Psychosis

Background

Mechanism of Action

Relationship to KarXT

ACADIA's AD Psychosis Program

Open-Label Extension Study Design

Purpose of OLE Studies

Study Structure

Outcome Measures

Safety Monitoring

AD Psychosis: Clinical Overview

Prevalence and Impact

Pathophysiology

Current Treatment Landscape

ACP-204 Clinical Development

Phase 1 Results

Phase 2 Findings

Phase 3 Program

Long-Term Considerations

Sustained Efficacy

Safety Profile Evolution

Combination Therapy

Regulatory Considerations

FDA Pathway

Approval Requirements

Post-Marketing Commitments

Competitive Landscape

Muscarinic Agonist Competition

Market Opportunity

Related Pages

Pharmacological Properties of ACP-204

Receptor Binding Profile

Pharmacokinetics

Comparison to Other Muscarinic Agonists

Clinical Trial Methodology

Open-Label Extension Design

Assessment Schedule

Data Management

Safety Monitoring

Adverse Event Collection

Laboratory Monitoring

ECG Monitoring

Special Populations

Efficacy Assessment Details

Neuropsychiatric Inventory (NPI) - Psychosis Domain

Clinical Global Impression of Change (CGIC)

Mini-Mental State Examination (MMSE)

ADCS-ADL (Alzheimer's Disease Cooperative Study - Activities of Daily Living)

Statistical Analysis Plan

Sample Size Justification

Efficacy Analyses

Safety Analyses

Regulatory Considerations

Long-Term Safety Database

Labeling Implications

Post-Marketing Requirements

Competitive Positioning

Market Analysis

ACP-204 vs. Competition

Strategic Advantages

Future Development

Potential Follow-On Studies

Adjacent Indications

Combination Approaches